Abstract
Many targeted treatment methods have focused on SARS-CoV-2's spike protein, along with neutralizing monoclonal antibodies (mAbs), which are recombinant proteins, may be employed as a kind of passive immunotherapy to reduce pathogenicity. While vaccines are still the best way to prevent COVID-19 infection, mAbs are an effective treatment for those who have already been infected, as well as having the potential to prevent infection in those who have already been exposed to SARS-CoV-2, which can be especially beneficial to certain high-risk groups. Due to the limited initial availability of these new treatments, it is essential to consider their larger potential and create methods for their optimal deployment in clinical practice. The objectives of this review is to answer the most commonly asked clinical questions from HCPs and patients about the target population, dose, interactions with other medicines and vaccines, duration of immunity, and variants.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
